China deals a blow to a semi giant, and a new combatant in the Battle of the Bulge Description 5/22/23

22 May 2023 · 47 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" - 5/22/23

Episode Overview

  • Title: China deals a blow to a semi giant, and a new combatant in the Battle of the Bulge
  • Host: Melissa Lee
  • Guest Traders: Tim Seymour, Steve Grasso, Dan Nathan, Mike Coe
  • Main Topics:
  • Micron's stock drop following China's ban
  • Debt ceiling negotiations in Washington
  • Pfizer's entry into the weight loss drug market

---

Key Discussions

  1. Micron and U.S.-China Relations
  2. Overview:
  3. Micron Technology faced a ban from China, listed as a national security risk.
  4. Shares dropped nearly 3%, making it the worst performer on the Nasdaq 100.
  5. Reaction from the U.S. Commerce Department denouncing the ban as unfounded.
  • Analysis:
  • The ban represents escalating tensions between the U.S. and China, previously hinted at since 2019.
  • Tim Seymour pointed out the potential for retaliation, referencing the historical context of trade conflicts.
  • Discussion on the implications for other semiconductor companies like Qualcomm and Broadcom, with varying levels of dependence on the Chinese market.
  • Market Implications:
  • Traders debated whether this presents a buying opportunity for stocks less reliant on China.
  • Tim raised concerns about the long-term impact of geopolitical tensions on the markets and individual companies.
  1. Debt Ceiling Negotiations
  2. Overview:
  3. President Biden and House Speaker McCarthy met to discuss the debt ceiling.
  4. Expectations for a deal were low, but both sides acknowledged the need for compromise.
  • Market Reaction:
  • The potential for further market volatility if a deal isn't reached.
  • Traders expressed skepticism about the market's current stability amidst political posturing.
  1. Pfizer's Weight Loss Drug
  2. Overview:
  3. Pfizer announced positive results for its new oral weight loss medication, hinting at competition with Novo Nordisk's Ozempic.
  4. Stock price surged after this announcement.
  • Expert Insight:
  • Colin Bristow from UBS highlighted that while the results are promising, they may not significantly outperform existing options like Manjaro and Ozempic.
  • Concerns raised about the high discontinuation rates of Pfizer's drug compared to competitors and the overall market positioning.

---

Key Takeaways

  • Geopolitical Tensions:
  • The ongoing U.S.-China tech conflict is impacting stock prices, particularly in the semiconductor industry. Investors should watch for further developments in international relations.
  • Market Positioning:
  • With the debt ceiling looming, cautious investor sentiment suggests that any potential resolution might lead to a "sell-the-news" reaction in the stock market.
  • Pharmaceutical Developments:
  • Pfizer's advancements in weight loss drugs could signal a shift in market dynamics, but its relative competitiveness remains uncertain.

---

Final Thoughts The episode underlined the intersection of geopolitical issues, financial market reactions, and industry-specific developments, indicating the complexity of navigating the current investment landscape. As tensions rise and companies innovate, traders must remain vigilant and adaptable to shifting circumstances.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Right now on fast, President Biden and House Speaker McCarthy meeting minutes from now on the debt ceiling. The speaker saying ahead of the sit-down, the talks are at a sensitive point. We'll get the very latest from Washington coming up. Plus, Jamie Dimon says the market should get ready for rates to keep climbing. He also said he can't do his job forever but feels great about the next generation of leadership. The details from the JPM Investor Day straight ahead. Later, Pfizer gets set to get into the obesity game. New results in a pill form of their weight loss drug that they say may be as effective as the shot from Ozempic will go inside the numbers.

0:35And Foot Locker getting kicked around again today. And look at all the retail names getting dragged down along with it. I'm Melissa Lee. This is Fast Money. We're live at the Nasdaq MarketSite. On the desk tonight, Tim Seymour, Steve Grasso, Dan Nathan, and Mike Coe. We start off with the latest blow to an already strained U.S.-China relation. Beijing initiating a ban against Micron, listing the U.S. chipmaker as a risk because it failed a national security review. Micron slipping almost 3 percent on the news. It's the Nasdaq 100's worst performer today. The U.S. Commerce Department criticizing the China decision.

1:07A spokesperson stating, we firmly oppose restrictions that have no basis in fact. So what impact will these rising tensions have on the markets and the economy? And to some extent, we are girding for this. We are preparing for this. We thought this would happen. They were placed under review months ago with the tech ban on the U.S. We thought there would be some retaliation. Tim? Yeah, I think we've been bracing for this for a long time. And on the show, we've been talking about this. And I think we've posited that actually could exist not just within the tech sector. And I think as you get into consumer products, but it's been very easy for any government from the beginning of time to lean back on.

1:39I think the call here is critical infrastructure. Now, really, if this is a tit for tat, the first part of that expression started in May 15th, 2019, when when Trump then banned Huawei. and again talked about telecoms info and those companies that had exposure to critical U.S. infrastructure on the telecom side. So seemingly this has been going on. At least the intensity of this this battle has been going on for three years. Obviously, there are a lot of geopolitics here because you think about South Korea, you think about Samsung, you think about SK Hynix, and you think about that. Basically, there's three players that produce 95 percent of the world's DRAM.

2:18And so it's going to be an issue and it's going to require that the U.S. lean on their allies. And it's going to require that China push back. And it's going to require that we have these escalated tensions. And I think it's just the beginning. You know, it's interesting that they chose Micron here. And again, this has been under review for a couple of months. If you think about Micron, I think in 2021, 11 percent of their sales come from China. But Qualcomm has 65 percent of their sales from China. Broadcom has 35 percent. Intel has 27 percent. So they picked a very commoditized product, which is memory is DRAM.

2:47And, you know, so I think it's kind of interesting. It feels kind of benign. I thought the stock's reaction, surprisingly, it was down like 4 % or 5 % pre-market. And then it was at one point down about 2 % or so. And it's still highs. Yeah. Yeah. You know, so it's kind of interesting to me. And then here's a company that, again, pretty cyclical sort of stuff. They were dealing with shortages. Then they were dealing with gluts. And then, you know, if you look at their earnings and sales down 50 % year over year right now, they're kind of working through all of that here. So, again, I think the point is that this is not going to end anytime soon.

3:18I also thought it was weird as Biden's coming back from the G7, those headlines about, well, expect our relations to get better. I don't know where that comes from. Yeah, it's kind of odd. Something like that. Yeah, I mean, and the timing of it is not, I mean, think about the communique from the G7 talking about de-risking from China. That came out. And then just hours later, this ban comes out on Micron. So it really does seem like, oh, you do that to me, we'll do this to you. Right. So when Dan gave the breakdown of the revenue that's derived from China, Qualcomm is beaten up. The stock has been beaten up for a host of other reasons to begin with.

3:50But when you look at AMD, that stock hasn't been beaten up for a host of other reasons. Micron, which is interesting, what's been the pixie dust lately? AI. And what does AI need to run on? NAND. So this to me is all a buying opportunity because it's not so dependent on China to begin with. On Dan's scale, this was one of the lowest that were dependent on China. And I think it's actually worth a visit on the buy side. 11 percent of revenues from mainland China in the past fiscal year, Mike Ko. It did seem like a warning shot precisely for what Dan had mentioned. I mean, this is, you know, the chips that are needed for critical infrastructure.

4:29That's a very small part of what Micron sells into China. It's mostly for consumer devices. And so this felt sort of like, you know what, this is the way it feels on the scale. But we can ratchet that up. Yeah, I think this is a much more symbolic type of a gesture for sure. I mean, consider WPG in Taiwan. They actually generate more revenues for Micron than basically all of mainland China does. And as you point out, the affected areas, that's not going to encompass all of that 10 percent. I think Dan's really getting to the heart of the issue, though, which is that, you know, we're seeing these big revenue declines for Micron.

5:03And that is because, you know, demand for the products that their chips support is just not there. It is trading already a little bit of discount to the market at about 17 and a half times. You know, people that over the last 10 years have averaged about 380 a share. Yes, that's the number I'm going with, you know, and it's a sector business. So it should trade at a discount, especially in the current environment. I think this is, as Carter often likes to say, a pair of twos. This isn't one that would be chasing on a mild decline like the one we saw today. I mean, the overall impact on the on the socks is pretty de minimis.

5:36I mean, the socks was up a fractionally, pretty much in line with the markets. I mean, is this a reason, Tim, you would sort of rethink an investment in a Qualcomm or a Broadcom or any of these other chip makers that sell into China because of this threat of escalating tensions? The answer is yeah. And I think we've just kind of begun to figure out what the discount rate is. But again, I think you think more about critical customers. And to the extent that Qualcomm's been an Apple story. it's been thinking about where people have their exposure. I guess I ultimately look at where we have been in terms of why Micron is more or less near kind of the top of a one-year range and why it's been working its way through what has been an oversupply and falling prices in DRAM and NAN that have stabilized.

6:24And we've had different cyclical reads on this. But I do think that, you know, it's the same kind of argument that I think we put I think we put a bit of a discount on Taiwan Semi at times when we were really talking about China, Taiwan and where conflict was critical there. And also where at some point the U.S. may say, hey, you know what, you're too close. And so I think there's going to be a reassessment of all of those firms that I've explored. And isn't it all about the CHIPS Act anyway? So this started a while ago. So if that whole fight started somewhat a distance ago for the overall market, you're going to see this play out a little bit.

6:59What you think what I think you need is more people to get on the U.S. side versus China side. And maybe it helps them to ratchet down the rhetoric versus to ratchet it up. And where we're at right now is the ratcheting up of rhetoric from China based on what we heard today. And I hear you. But who can join the U.S. side here? I mean, again, can South Korea, who's a major ally who just got back from the U.S. and sang American Pie or whatever, you know, I mean, but what can they really do? I'm just saying other countries, too. So just just just on a rhetoric basis, maybe Europe can start toning it down or ratcheting it up against China, because China really doesn't have a leg to stand on a lot of these human rights issues.

7:39And it's odd to me that we're always playing sort of defense when it comes to China, where the whole world is bringing up the human rights element. And China seems to be pushing that aside and powering forward on the business level, where I think we should be looking at where the puck is going, not where it is. Well, I just say one thing on that, which is very clear. If you're a CEO of a U.S. multinational, you think to yourself like, OK, we've been in a 2 percent growth environment GDP wise for a very long time. Two thirds of that GDP comes from our consumer. But over there, they have a rising middle class that is greater than the size of our entire population.

8:13And it really is all about this emerging consumer in a way. And I know that a lot of people now are very focused on India in the same way. But because we've had such a tight relationship from a supply chain situation, manufacturing, it has worked. And it's worked that we've actually disregarded some of these human rights sorts of issues. I mean, not me. I mean, we're all saying we all. But you hear what I'm saying. No, 100%. It's odd to me. And by the way, the consumer in China really hasn't come back the way that we thought the consumer would come back because China can throttle that growth whenever they want.

8:45And they seem to be tamping it down to spike themselves. And I don't get that either. I think it's a tailwind, by the way. I think China growth in the second half of 23 is something that people are underestimating. And I would just get back to a lot of the big themes that we thought about why Intel is spending tens of billions of dollars and why they are going to be partnering with another number of infrastructure firms. All this nearshoring, all of this new strategic relationships is very inflationary. It's very time consuming. It's not going to happen overnight. And I just think that that's the world we live in.

9:15I think so back to a question is what's the discount you put on some of these companies that have to rely on China? I think you have to think about it. I get back to a market where Apple's smartphone share in China is 22.3 percent last time I looked. And that's major. And we, you know, Tim Cook has done a phenomenal job of kind of navigating below the radar screen. But at some point, Apple has the biggest target on their back. The authority issue, though, or the conundrum is that you put a discount on the companies that rely on China, that operate out of China. And you and you also put it sounds like a discount on companies that are going to be nearshoring because it's inflationary.

9:48And I mean, it's sort of like in this transition period, it's going to be very difficult. But listen, Elon said it last week to David Faber. I mean, like he took all focus back on Apple, to your point. And, you know, when you think about their exposure there, just obviously from a sales standpoint, from a manufacturing standpoint and all the investment that they have made on that, I do think it's kind of interesting here. And I look at that Apple chart, man. That looks like the mother of all double tops. And to your point, Mel, there is no discount placed on an Apple trading where it is at 27 or 28 times or anything like that.

10:19So there's no discount anywhere in the market that I can find for any of these things, these headwinds that we detail, whether it's the debt ceiling, whether it's slowing growth, whether it's a deep recession. There is no discount anywhere. And I think we're just back to a YOLO market here. And last thing, just just to make it a trading thing, because obviously Dan sees a double top. I see a breakout in Apple and that's what makes markets. Yeah, there you go. For more on all this, let's bring in Yale University senior fellow Stephen Roach on the fast line. He's a former chairman of Morgan Stanley Asia.

10:49Stephen is also the author of Accidental Conflict, America, China and the Clash of False Narratives. Stephen, great to have you with us. What did this ban on micron feel like to you? Was it symbolic? Do you think that this is just the first step in many that China will take? Well, thanks, Melissa. I'm surprised it took this long. Actually, they telegraphed this, as you said, at the beginning of the show in early April. And I think we just have to step back and take a deep breath. The U.S. took major action against China's technology in early October with these draconian export sanctions on China's access to advanced semiconductors.

11:38They need those chips for their key innovations in AI and quantum computing. The U.S. also corralled a couple of allies, Japan and the Netherlands, to join in these sanctions, in this case, squeezing out China's access to the semiconductor production technology. So these are major, major actions that we took, we initiated. Our justification is we've lost patience with China's failure to distinguish between civilian and military applications of technology. So we're going to squeeze them in the entire space. the retaliation against micron technology is peanuts compared to what we have done to China.

12:37So I think your gang sitting there is right to think that there is more to come. I have no idea who will be next. Somebody just talked about Apple is having the biggest target on its back. That's, you know, certainly correct. But we have no idea if they would dare to do that, given the commitment that Apple has made to offshoring in China, even though they're starting to move a little bit away. But this is just the beginning of what I think is going to be a series of major battles in the tech war. Stephen, you mentioned that our actions versus China were draconian back in the fall. And so let me ask you this.

13:19When you're thinking about something that is so important, you just mentioned it to a whole host of industries in China, access to these advanced chips. Does this sort of ban force them to come up to speed and actually make them more competitive in doing it this way? Does that become more of a risk for maybe U.S. manufacturers here? Absolutely. I mean, that's precisely their response. But as you guys alluded to earlier, China's been talking the talk about bringing their domestic semiconductor industry up to world standards now for years and years. It's a difficult thing to do. And so they are redoubling their efforts right now.

14:00There's no question about it. And I'm confident they will get there. But it's not going to be this year or next year. It's going to be several years out. And in the meantime, they are very vulnerable to the restrictions that we're imposing on their access to the chips they need to drive their indigenous innovation. In the China playbook, Stephen, is it your view that the retaliation for the CHIPS Act will remain within the tech sector, or could it go another route and hit another industry? Look, there are no rules that require a tit-for-tat to be exactly in the same industry that the initial actions were taken.

14:41We've done that a lot. We started out with a trade war that was very narrow and then accelerated into a tech war. And now we're talking the talk of a Cold War. But in doing that, the issues have moved from trade to human rights to economic coercion. I mean, we're not at a loss of rationales to come up with, and they keep morphing from one to another. So I wouldn't be surprised if China were to follow the same script in its own retaliation. Stephen, as you think about it, and certainly in your role in Morgan Stanley back in the day, you've been a pioneer for capital markets in that part of the world, and you understand those markets, and you see how under-invested EM is, and you know that China's 40 percent of EM.

15:31Do you see a world where we can decouple this kind of story? Because, you know, to the extent that China has also been a very difficult place to invest for people, We're talking about American firms and the exposure over there. But just investing in China, you know, can you give us just your couple of thoughts here on whether the fundamentals of the economic growth that I think is going to maybe surprise people in the second half of the year relative to where everything's priced? You know, can you make a call on that? Yeah, I can. It's an uncomfortable call. I've been a congenital bull on China for 25 years.

16:03I do buy the point that you're making about stronger than expected growth in the second half of this year. But I'm worried about 2024 through the end of this decade because China's got some structural problems that they're finding very difficult to address. Demographies are given their working age population is going to be shrinking for years and years to come. And so they need more productivity growth to offset that. And by focusing on state-owned enterprises as a source of growth where productivity is the weakest, they're not going to get it there. And by putting pressure on the private sector, especially the Internet platform companies, as they have unfortunately done over the last couple of years, they're not going to get it there.

16:52So I'm sort of stuck in a much more challenging and difficult medium to longer term growth call than I've ever had on China. in the period that I've been covering them. All right, Stephen, great to get your thoughts. Thank you so much. Thank you, Melissa. Stephen Roach of Yale. The other twist, I mean, if the U.S. goes into a recession, then the manufacturing sector in China doesn't catch a break, Tim, right? And so that's another area of pressure on the economy. I think companies that have a lot to gain by China are European companies. And I think of some of the big exporters from Europe into that region.

17:28And I think that's another one of the reasons why international looks a little bit more interesting, especially with the currency implications. I would just say I do think they're different. And I do think that we've talked about Baba and where it's still a trade. It's not an investment. And I look at, you know, a year of consolidation and a lot of these names, all things being equal to the environment we have today. I think Baba is going higher. I think there's a trade here. And again, the sum of the parts and the spinoff of their cloud company is is a catalyst. a lot of these, whether it's the FXI or the K-Web or even the EEM, all ways to play China, are kind of right up against some levels.

18:00And if the dollar weakens, I think they all go higher. Think about the other, the EV industry that's staring us in the face. You heard Farley, the CEO of Ford, mention it today. You could buy up all the lithium and copper and cobalt that you want, but 80 % of the processing is done in China. That's the next one that could, they could really tighten the noose around America's next as we start to segue into more EVs. Coming up, all the headlines out of J.P. Morgan's Investor Day, what CEO Jamie Dimon had to say about growth, the economy and much more. We've got the details next. Plus, two sneaker stocks getting kicked.

18:33Shares of Nike and Footloaf are dropping again as analysts turn sour on the names. How the inventory overhang is impacting this space. Don't go anywhere. Fast Money is back in two.

18:50Welcome back to Fast Money. J.P. Morgan CEO Jamie Dimon warning of higher rates in a tighter credit market while speaking at the company's Investor Day today. The bank also upping its net interest income outlook for the year by$3 billion thanks to its takeover of First Republic. Leslie Pickers has been following the event today. She joins us now. Leslie. Hey, Melissa. Shares of J.P. Morgan closing in the red today despite that higher net interest income guide at the firm's Investor Day. Diamond spoke about the overall fallout from the bank turmoil we've seen this year and predicting there will be a credit cycle pointing to real estate as the offsides as the Fed continues to tighten.

19:28You're already seeing credit tightening up because, you know, the easiest way for a bank to retain capital is not to make the next loan. So I think you are going to see that. And I think everyone should be prepared for rates going higher from here. You know, if that five percent is not enough in Fed funds, if I and I've been advising this to clients and banks, you should be prepared for six, seven.

19:53Speaking of being prepared, succession was the key topic at the end of the Q &A in light of future movements within the C-suites of Morgan Stanley and Lazard. Diamond says he still has the grit to do the job. I can't do this forever. I know that. But my intensity is the same. I think when I don't have that kind of intensity, I should leave. I don't think CEOs should retire in place and just cut back and take it easy for a while. I think that erodes the whole company over time. now when asked how much longer he plans to be ceo he chuckled three and a half more years likely a nod to that stock option bonus he got in 2021 all right leslie thanks leslie picker from the jp morgan investment day meeting it's interesting to hear to hear him say prepare for rates that are higher than five percent six seven eight and also in terms of credit reserves they're preparing for peak unemployment of 5.8 % in 2024.

20:51Is this all just being extremely conservative because that is the safer thing to do? Or do you think that there is a belief that rates could go to 6%, 7 % and 5.8 % unemployment? I don't think he would have said that if he doesn't think about it. And then you think about all this Fed speak that we've seen really that got started with Lori Logan last week and Kashkari. And I mean, these folks seem really determined to break the back of inflation without acknowledging the fact that inflation is likely to stay more elevated than they had hoped prior to the pandemic. And the likelihood now is that whatever you think normal rates are, they're going to be much higher for longer, and whether it tops out at 6 % or 7 % for Fed funds.

21:31I don't know how the stock market closed unchanged. There was a world that we used to live in in the stock market where if someone told you that the CEO of the largest bank with the most credibility on the planet said, be prepared for much higher rates, that means for longer, and equities could just stay bid here, That seems very odd to me. Yeah. Mike. Yeah, I agree with Dan wholeheartedly here. I mean, we've got a lot of things sort of working in concert in tandem that I think are going to pressure this. First of all, there is just the supply and demand for money issue. I mean, I do believe that, you know, the inflation genie is a tough one to stuff back in the bottle.

22:07So for those that are expecting some kind of rate cuts in the near term future, I just don't see that happening. And of course, that's the short end of the curve on the long end. Basically, if you start to see some credit tightening within the banks and there's still demand for it, that's obviously going to create a problem. And there's something else, too, which is that when we think about what a normalized rate condition should be, most people are only looking back with a lens that goes back to the GFC, which is not a realistic lens to use. I mean, if we just go back a little bit further than that, the rate environment in which we currently find ourselves is not so extraordinary.

22:42And I think that's really what people should focus on. We We got away with very cheap and plentiful money for a decade plus, and that just can't go on forever. And I don't think we should expect it to return anytime soon. And that's going to create a lot of pressure in a lot of areas. All right. There's a lot more Fast Monday to come. Here's what's coming up next. The other shoe has dropped. Analysts tripped up on Foot Locker results, and they think Nike could follow. It's time to lace up. More on the footwear flop next. Plus, the latest on debt ceiling negotiations. So can lawmakers strike a deal?

23:20The economic impact as the deadline draws near. You're watching Fast Money, live from the NASDAQ market site in Times Square. We're back right after this.

23:39Welcome back to Fast Money, a double shot of buzzkills in the athletic workspace. FIT LOCKER SHEDDING ANOTHER 8.5 % TODAY. THAT IS ON TOP OF ITS 27 % POST-EARNINGS DROP FROM FRIDAY. CITI DOWNGRADING THE STOCK TO A NEUTRAL, SLASHING ITS PRICE ARGET TO$30 FROM$48. THE BANK ALSO PUT NIKE ON NEGATIVE CATALYST WATCH, CITING HIGHER INVENTORY LEVELS AND A MORE CAUTIOUS CONSUMER AS REASONS FOR CONCERNS AHEAD. THOSE SHARES DOWN ABOUT 4 % TODAY'S SESSION. WE TALKED ABOUT THAT. WE REALLY SURROUNDED THE TRADE ON FRIDAY. Who knew how much pressure the stocks would continue to feel today, Tim? Well, you know, we talked about where Nike is what percent of sales of Dix, excuse me, of Foot Locker and where they've got a read through to not only people like Dix, but, you know, Deckers, all kinds of.

Read the full transcript

24:22But lower income consumer is what's in focus here. And what we forget to talk about is that, excuse me, Foot Locker is 9 to 10 percent of Nike's North America sales and 6 percent of their global sales. This is significant, but it's a read through to their inventory. And there's a read through to a lower income consumer. And there's a discussion about inventory. And there's now a presumption and at least a question within the analyst community as to what are they going to do with sales versus margin? Are they going to promote their way out of this and knock down the inventory and kill their margin?

24:51And they might. Look, I'm short Nike and I'm short it for the last six to eight weeks, not because it's a terrible company. But for honestly, these reasons, I just don't think this multiple is supposed to hold up, especially with a major pull forward. And I do think we're going to start to see it from the lower income consumer. And it's going to feed through. It's going to feed through to Lulus multiple. When you look at Foot Locker on a chart, it ripped through those October levels 2022. And the problem that you have with these stocks is that the analyst community always after the event, they always rush in.

25:21And there's always the downgrades that follow on. And that's what we saw. And you probably see a little bit more of it in the next couple of days. But I think you have to wait and take a shot at it at around 23, which is a big gap from where it is right now. But that's the support I see, and that's the July 2022 levels. I would take a shot there. But if you want to take a shot here, don't do it all at once, 25%, and do a couple of those. You seem to like Dick's because you mentioned it a few times. But when I look at this one and I think about, like, less of exposure to a Nike and more diversified, this one's kind of interesting to me, but it just broke that uptrend that had been in place since mid-2022.

25:57So I think the whole space appears to be softening a little bit here. All right. Coming up, President Biden meeting with House Speaker Kevin McCarthy for debt ceiling negotiations. That meeting kicking off any minute now. We'll bring you the details as we get them. And RBC's Lori Calvacino will help us break down the headlines as we get them. The impact on the markets and your money straight ahead. Fast Money's back in two.

26:23Welcome back to Fast Money. Stocks largely flat as debt ceiling negotiations continue. The Dow dropping 140 points. The S &P virtually unchanged. And the Nasdaq higher by half a percent. A big energy deal making headlines today. Chevron buying shale firm PDC Energy in a stock and debt deal worth more than$7 billion. Chevron saying the move will increase the company's oil and gas footprint in the United States. And in the after hour, shares of Zoom giving back early gains after reporting results. The company posting a beat on the top and bottom line, raising guidance for the year, but not as much as their beat.

26:55Stocks up less than a percent now. Turning to the debt ceiling talks, President Biden meeting now with House Speaker McCarthy as party leaders try to reach a deal and avoid a U.S. debt default. CNBC's Kayla Towshey is at the White House with the latest. Kayla. Melissa, that meeting is expected to happen momentarily. It's the first time in a week since the two sides appointed a smaller group of deputies to lead negotiations. And Speaker McCarthy is currently on his way over to the White House from the Capitol. Those talks have still been alluded by big picture items like the levels of government spending and the time frame of any budget caps, which are critical top lines even before getting down to nitty or grittier details.

27:32Republicans have proposed increases to defense and border spending with steep cuts to other programs, while the White House proposal would keep discretionary spending flat. Given the distance in those positions I just laid out, a White House official tells me expectations are low for a deal tonight. But Speaker McCarthy earlier today said it's possible. I thought it would be better to have a deal sooner. I think we can get a deal tonight, we can get a deal tomorrow. But you've got to get something done this week to be able to pass it and move it to the Senate. He said to get a deal, tough decisions would need to be made.

28:06And ahead of the meeting today, Secretary Yellen updated Congress on the deal deadline and said by as early as June 1st, it's highly likely the government can't pay its bills. A week ago, the secretary said it was just likely. We're also expecting to hear directly from Speaker McCarthy when the meeting concludes, and we may hear from President Biden as well. We'll see what sort of tone they're striking after that meeting concludes, Melissa. All right, Kayla, thank you. Kayla Toschey from the White House. For more on all this, let's bring in Lori Calvacino, RBC's head of U.S. equity strategy. Lori, great to have you with us.

28:39I mean, everybody's watching this, but when it comes to the market's performance, even over the next six months, how important is this? Well, thanks for having me as always, Melissa. Look, I think that this is a huge issue right now. As I've talked to investors over the last month or so, some of the more bearish people we've talked to have been very focused on the debt ceiling as a potential trigger to see a short-term drawdown in the U.S. equity market. And frankly, a lot of those investors are coming from outside of the U.S. They are people who are inclined to be negative on the U.S. for other reasons as well.

29:11But I do think that if we can get a deal here, it is going to remove an important issue that the bears have really been pointing to in coming months that could pull this market down. How do you view where those drawdowns might be from, Laurie? I mean, is tech, because it's seen the biggest gains, is that the area? Or is tech, because it's defensive, will that be safe, relatively speaking? So it's a great question, Melissa. And the answer is it's a little bit of both. We actually went back and we've mapped out the equity market response to every single drawdown around the debt ceiling going back to 2011.

29:44And when we looked at sector performance within the S &P during those drawdown periods, we found that the worst performing areas were the value-oriented sectors, financials, energy, materials, and industrials. The defensive sectors obviously held up the best, though health care was the worst performing defensive and tech and the growth sectors were right smack dab in the middle. So I do think that tech gets hurt, but it probably holds up better than some of those more cyclically oriented areas if we don't get a deal. So, Lori, we haven't really seen the market come in at all. It didn't come in on earnings.

30:17And I think what kind of masked it was earnings were bad at the back half of 2022, but energy sort of masked that. Now, when we're looking at the debt ceiling negotiations, the market has not stuttered or taken a step back. So when we eventually see this deal, A, do you think the deal is going to be done in the 11th hour? Because it doesn't behoove either side to get a deal done before the 30th of May. And B, where does the market rip to if it does rip at all? Or do you think that's totally factored in? So, look, I think that's a bunch of great questions. And I would say last year, we do think the equity market essentially priced in a recession at those October lows, really pre-traded 2023 back in 2022.

31:01And I think one of the reasons why the market hasn't drawn down that much is that the markets understand that this has happened before. Now, when I talk to non-U.S.-based investors, they're very worried about the debt ceiling. When you talk to U.S.-based investors, they're feeling increasingly worse about it, but they're like, OK, you know, a deal generally does get done. So I think people in the states have been holding their breath understanding how this political theater tends to play out. And so what we've seen is really more rotation than pulling money out of the market because of that latter group of investors thinking something will get done at the 11th hour.

31:34I think what's been interesting to me about this debt ceiling issue is that it's just been another excuse for investors to rotate into tech and growth stocks and pull money out of cyclicals. You know, kind of we pre-traded the Fed pause at the beginning of the year. It's bigger that rotation. Then we had SVB. Then we had these great tech earnings. And this is like the fourth thing we've had that's pushed people into tech stocks because of a rotation argument. So I think it's fascinating. You know, I will say in terms of, you know, kind of potential upside from here, you know, we're at 4 ,100 on the S &P as our year-end target.

32:04We still like that number. We do think valuations are about where they deserve to be. But I'll be honest with you, I have some models that could take us up to 4 ,200, that could take us up to 4 ,300. So we have said we see more upside risk than downside risk to the market this year. That being said, we've got to get through this debt ceiling issue. I mean, this is really a significant hurdle we've got to get through. I am optimistic because the two sides are finally talking. But I do think it makes sense that people have been waiting and holding their breath to see what happens. A reason for optimism is two sides talking.

32:35That's kind of a low bar. But, Lori, always great to get your thoughts. Thank you. Thanks for having me. If we've already pre-traded, is there a sell the news event? I mean, is reaching a deal a sell the news event, Tim? I think so. And if that's so, do we see the sale happen in technology? Well, I just, look, the flight to quality here, you know, we can look at NASDAQ and we can see Microsoft's down 4 % from all-time highs. Apple's 6. Google, which seemed like it was an uninformal, 0.9 % down from all-time highs. So there's no question tech's been defensive here. 500 basis points higher in rates.

33:10These stocks just don't belong at these multiples. But, you know, what's also going to happen, if just say we got downgraded and I don't think it's going to happen, Treasuries will rally. They'll rally like crazy. And the dollar will rally like crazy. And some of this will be very good for markets at some point. So, and again, after it's really awful for markets. But I do think right now equities have priced in very little. And if anything, they've kind of rallied in the face of this. And, yes, I think there's going to be probably a sell the news. Yeah. Mike, your take? Yeah. I mean, take a look at what Yellen has said she thinks the deadline is.

33:41and then take a look at how the options markets are implying that the S &P is going to move over the course of that same time frame. So we're now looking out to, let's call it the third or fourth week of June. And if you take a look at the at-the-money straddle for the S &P, this is only about 3.3%. And what that tells me is that a lot of investors, certainly stateside, really believe that there's going to be an end to this before some sort of crisis is reached. And I think if that is true, if they're baking in a solution, then it's hard to see why you would buy it if you got one, because that is what is already expected.

34:12So I'm with Tim. I think you would have to sell that. All right. Coming up, office vacancies taking a toll on the real estate space, the regions and stocks most at risk as a work from home trend persists. That's next. Fast Money's back in two.

34:33Welcome back to Fast Money. Big cities facing big problems when it comes to empty office space. The high rate of vacancy has driven price per square foot down to less than half of pre-pandemic levels, according to new data. Our Diana Oleg joins us now from Los Angeles with the story. Diana. Well, Melissa, Los Angeles may be a smaller office market than Manhattan, but it has even bigger problems. The office vacancy rate in L.A. soared to 22.5 percent in the first quarter this year. It represents 50 million square feet of non-leased office space, about 61 percent more than pre-pandemic. And L.A.

35:07office leasing volume in Q1 of this year also weighed down. What is leased, though, is still not being used very much. The average occupancy in L.A. is 49 percent, slightly lower than the national average. L.A. is not quite as bad as San Francisco, where the vacancy rate is 23 percent. But looking across the nation, Chicago at 22, D.C. actually at 18 percent. And Manhattan, even though we touted that it hit this record high vacancy, it's at 17%. So let's talk LA REITs and stocks involved in this. The ones with the biggest exposure are Douglas Emmett, Kilroy Realty, and Hudson Pacific properties.

35:41The first two down about 25 to 30 % year to date and Hudson Pacific down over 50%. Douglas Emmett by far though has the most exposure, but all of these are heavy in West LA or in other areas surrounding downtown LA. And as with everywhere else, there is a flight to quality with newer buildings that have more amenities seeing more demand, older buildings suffering more. Melissa. All right, Diana, thank you, Diana Oluk. And, of course, for seeing the pain felt across office freets in particular. SL Green, I mean, today was a good day for Bernado and for SL Green, but SL Green was trading at levels not seen since its IPO back in 1997.

36:19Mike, what's your take on the pain in this space and whether or not there's more to come? Yeah, I suspect that there's going to be more to come. awfully negative today, I guess, when we take a look at it. And of course, I'm based in the San Francisco area. So it's easy for me to be negative when I think about basically anything in the commercial real estate side, because it's a pretty dismal picture out here. When you see these occupancy rates, that's part of it. And when you see the lease rates, that's certainly part of it. When you see where these buildings, that's the assets that underpin these businesses are actually valued.

36:51We've had some big office properties trade just recently at 80 percent discounts to where they were valued just a couple of years ago. And these are these are buildings that are going to need significant investment if they're going to try to be competitive. I just don't see a lot of people rushing in to buy these things. And that's a really difficult situation. You have levered businesses. You have asset values falling precipitously and no cash flow. That's that's not a healthy mixture. When you look at the maturity wall that we've all been talking about in the commercial real estate world, if Jamie Dimon's world happens and we're looking at interest rates rising from here, then you're not going to be able to make this story any better.

37:31So every time you try to bottom fish and bargain hunt in this sector, it's collapsed further on you. So I would wait to see what rates do first. Coming up, Pfizer entering the ring in the battle of the bulge, and the results could give Ozempic a run for its money. Get the details when Fast Money returns.

37:55Welcome back to Fast Money. Pfizer jumping more than 5 % after a peer-reviewed study found the drugmaker's orally ingested weight loss treatment may be as effective as Novo Nordisk Ozempic. The dosage of Pfizer's drug is much higher than that of Novo's injectable, helping trial participants drop weight in less time. Shares of Pfizer seeing their best day since December 2021, now 7 % off its recent lows. For more, we're joined on the Fast Line by Colin Bristow, the Managing Director of Biotechnology at UBS. Colin, great to have you with us. You say straight off the bat that this is the same data cut that we saw earlier.

38:29So you're saying the markets are getting this wrong? Yeah, I think there's been a bit of a knee-jerk reaction and maybe a sort of misperception in terms of what's really new or kind of novel to the market here. And we saw the headline weight loss figures first presented at a diabetes conference in September last year. And then Pfizer reemphasized them at their pipeline day in December. So there's really not a ton that's new here that would really sort of change our perception of this drug in terms of the competitiveness of the clinical profile. You've got a neutral rating on Pfizer. I mean, if this is not going to get you more excited, this data cut doesn't get you more excited.

39:07You know, Pfizer still has dwindling COVID-19 sales. It's got a patent cliff that it's facing. So what will help this? More data, further data on this weight loss drug? Yeah, I mean, so let's talk about a few important points here as to sort of what's holding us from getting too excited. So aside from the fact that the data is not new, the actual weight loss efficacy is still inferior to what is many consider this sort of key weight loss struggle that the market leader being Manjaro, which has seen up to 21-22 % headline weight loss figures. So what we're seeing today is significantly below that.

39:45What we're looking at is in the type 2 diabetes population where Manjaro has shown around a sort of 13 % weight loss at the end of the study. Furthermore, this is, you know, on a sort of pure diabetic standpoint, this is a less competitive agent that the headline figures are inferior to a Zempic and Manjaro. And one thing that's really important here is the discontinuation rate. So at the highest dose of Daniel Glepon, the drug we're talking about, it was the 34 % discontinuation rate. That's three to four times higher than what we're seeing with Manjaro or Zempik. Another thing to consider, Daniel Glepon is dosed twice a day, so it's less convenient than the once-daily oral drugs being developed by Novo already.

40:30And then just finally, Pfizer are one year behind Lilly and maybe sort of two, maybe two to three years behind Novo. So these are all reasons why we're just, you know, we're being a little more measured here and not getting overly excited. All right, Colin, thank you for phoning in. Appreciate it. Colin Bristow of UBS. Tim, I immediately thought of you and your position in Pfizer. Well, what is very helpful here is that ultimately Pfizer doesn't get any credit for this drug. I mean, so if you think about what's actually been pushing Pfizer down is the sense of loss of growth from everything related to COVID.

41:04So the fact that there's a pie, there's a universe, there's an addressable market of weight loss drugs. And to that extent, this is certainly a gain for Pfizer. The fact that Pfizer had already talked about this at their investor event. They talked about this back in December. In some sense, it is a rehashing of old information. It's also an environment where we put very different multiples on drug companies because of exposure to that GLP-1 space. So diabetes and weight loss. That is now at least seen for Pfizer as an area of growth that's not at all priced in the stock. And if anything, I think it just offsets what is the sense of what do you do with Pfizer here?

41:40Right. You bought calls? Yeah, so I saw this news, and it's interesting. I mean, just think of the market catch shifts we've seen in this space and the differences in valuations and the sentiment so poor. So I saw this news, and I bought the July 40 calls. I've got 60 cents. I've got to cut you off. We've got to go to D.C. We're getting some breaking news here. Leaders are gathering to negotiate on the debt ceiling. Let's listen in here. And the consequence of failing to pay our bills would be that American people would have a real kick in their economic well-being. As a matter of fact, the rest of the world would, too.

42:13And so we also agree we need to reduce the deficit. And I might add, in my first two years as president, I've reduced it by$1.7 trillion in matters. So I'm all for reducing, continuing to reduce the deficit. and uh but we all we both talked about the need for bipartisan agreement we have to be in a position where we can sell it to our constituencies we're pretty well divided in the house almost down the middle and it's not any different in the senate so we gotta get something that can sell to both sides and we need to cut spending but we uh here's the disagreement we have to i think we should be looking at tax loopholes and make sure the wealthy pay their fair share i think revenue matters as well as as long as you're not taxing anybody under$400 ,000.

43:03So we still have some disagreements, but I think we may be able to get where we have to go. We both know we have a significant responsibility. With that, I'm going to turn it over to the Speaker. Kevin, it's all yours. I thank the President for spending time. We had a very productive conversation yesterday even though he was coming back from the G7 meeting. We do have disagreements. I think we have a 50-year average We're having more revenue at any time coming in. But I think we both agree that we need to change the trajectory, that our debt is too large. And I think at the end of the day, we could find common ground, make our economy stronger, take care of this debt, but more importantly, get this government moving again to curb inflation, make us less dependent upon China, and make our appropriation system work when we get done, right?

43:51I'm all familiar with appropriations work. Now they're out to be able to do it. Mr. President, is overall spending the way to resolve this to agree on that kind of number? I'm wrong. I'm wrong. I'm wrong. Thank you so much. Thank you so much. Thank you so much. Thank you so much. Thank you so much. Thank you. Thank you. If you can't stay on the patio, please go back to the room. Thank you.

44:31That's what's called a pool spray, because all the members of the press gather in one room, and they spray the room, and that's what you get, a sort of cacophony at the end. But they said that they feel they have common ground, that they could reach a deal. They know where they have to go. They're at least in the same room for this talk, Tim. I don't know if that makes you feel any better about avoiding a default. I haven't felt like we were going to default. I feel like there's enormous political posturing, and I think both sides have a lot to gain by certain stances that they're going to stick to.

45:03But it really gets back to the markets. Markets really have not priced in default. If we got a default, it would be a very significant shock to the markets. I'm going to say we're not getting that. And if anything, I think markets have rallied. If you look at just hedge fund exposure to S &P futures, for example, they're very, very underweight, the market here. So while I do think this is a sell the fact kind of a thing, I think positioning right now still remains very cautious overall for the markets. I think it's easy to be very political when you're not in the same room with someone. And I think it's always a positive when you see them in the same room and they have to be civil to one another.

45:38I think I think I'm looking at a May 30th deal. I think we're going to wait till the end of it. But we're going to have a deal either way. All right. It is time now for the final trade. Let's go around the horn. Mike Coe. Yeah, I'm kind of with Dan here. You know, we saw a lot of activity in Pfizer calls on the back of this news. Company is pretty cheap and all that COVID vaccine stuff's already been pulled out of it. Big Pharma in the final trade, Tim. Right. So let me go with Lilly, a stock that certainly we've been long with clients for a while. But I just think the multiple here, you've priced in so much good news.

46:10What is Pfizer's gain is actually Lilly's loss on some level. Steve. The stock that has been horrendous on a performance basis. Rivian is finally starting to lift its head up. It's been terrible, but I'll take a shot. Wow. Dan? Yeah, so in Pfizer, I would just say define your risk. Look out a couple months. You can get a little of this lily pixie dust going. So much OA in the show, too. Why wouldn't you? Thanks for watching Fast Money. See you back here tomorrow at 5 for more Fast Mad Money with Jim Cramer starts right now.

46:45All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

47:20To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.

From the publisher

Shares of Micron dropping after China bans the U.S. chipmaker. What the latest move means for tensions between Washington and Beijing. Plus key lawmakers meeting at the White House to try to come up with a solution on the debt ceiling. And Pfizer gets in on the weight loss drug race and sees shares soar.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
China deals a blow to a semi giant, and a new combatant in the Battle of the Bulge Description 5/22/23CNBC's "Fast Money" · 47 min
Listen in VO